What are the names of metered-dose inhaler (MDI) medications, including long-acting muscarinic antagonist (LAMA) and long-acting beta agonist (LABA), used to treat Chronic Obstructive Pulmonary Disease (COPD)?

Metered-Dose Inhaler (MDI) Medications for COPD

The primary MDI medications for COPD treatment include LAMA inhalers (such as tiotropium), LABA inhalers (such as formoterol and vilanterol), and combination inhalers (LAMA/LABA, LABA/ICS, and LAMA/LABA/ICS triple therapy), with specific product selection based on symptom burden and exacerbation risk. 1, 2, 3

LAMA (Long-Acting Muscarinic Antagonist) MDIs

LAMA inhalers work by blocking muscarinic receptors in the airways, reducing bronchoconstriction and improving airflow. They are particularly effective for exacerbation prevention. 1

• Tiotropium (Spiriva Respimat) 4
• Umeclidinium (Incruse Ellipta)
• Glycopyrronium (Seebri Neohaler)
• Aclidinium (Tudorza Pressair)

LABA (Long-Acting Beta-Agonist) MDIs

LABA inhalers relax airway smooth muscle by stimulating beta-2 adrenergic receptors, improving lung function and reducing symptoms. 1, 5

• Formoterol (Foradil, Perforomist) 5
• Salmeterol (Serevent)
• Vilanterol (only available in combinations) 6
• Olodaterol (Striverdi Respimat)
• Indacaterol (Arcapta Neohaler)

Combination MDI Inhalers

LAMA/LABA Combinations

These provide superior bronchodilation compared to monotherapy and are recommended as initial maintenance therapy for patients with moderate to severe symptoms. 2, 3

• Tiotropium/Olodaterol (Stiolto Respimat) 4
• Umeclidinium/Vilanterol (Anoro Ellipta)
• Glycopyrrolate/Formoterol (Bevespi Aerosphere)
• Aclidinium/Formoterol (Duaklir Pressair)

LABA/ICS Combinations

These are recommended for patients with high blood eosinophil counts or COPD-asthma overlap. 3, 7

• Fluticasone/Vilanterol (Breo Ellipta) 6
• Fluticasone/Salmeterol (Advair)
• Budesonide/Formoterol (Symbicort)
• Mometasone/Formoterol (Dulera)

Triple Therapy (LAMA/LABA/ICS) Combinations

These are recommended for patients with frequent exacerbations despite dual therapy, particularly those with high symptom burden. 2, 3, 8

• Fluticasone/Umeclidinium/Vilanterol (Trelegy Ellipta)
• Beclomethasone/Formoterol/Glycopyrronium (Trimbow)

Treatment Algorithm Based on COPD Severity

1. Mild symptoms (mMRC 1) with FEV₁ ≥80%:

   • Start with LAMA or LABA monotherapy 2, 3

2. Moderate to severe symptoms (mMRC ≥2) with FEV₁ <80%:

   • Start with LAMA/LABA dual therapy 2, 3

3. High exacerbation risk (≥2 moderate or ≥1 severe exacerbation/year):

   • LAMA/LABA/ICS triple therapy 2, 3, 8

Important Clinical Considerations

• LAMA vs LABA: LAMAs have greater effect on exacerbation reduction compared to LABAs and decrease hospitalizations 1
• LAMA/LABA vs LABA/ICS: LAMA/LABA combinations are more effective than LABA/ICS for preventing exacerbations and have lower pneumonia risk 9, 10
• Pneumonia risk: ICS-containing regimens increase pneumonia risk, particularly in severe COPD 1, 3
• Blood eosinophils: Patients with blood eosinophil counts >300 cells/μL benefit more from ICS-containing regimens 3, 7

Common Pitfalls to Avoid

• Monotherapy inadequacy: Single bronchodilators are often insufficient for moderate-severe COPD; combination therapy provides superior outcomes 2, 3
• Overuse of ICS: Avoid ICS in patients with low eosinophil counts due to pneumonia risk 3, 7
• Device inconsistency: Using different inhaler types can lead to technique errors; single-inhaler therapy improves adherence 3
• Inadequate assessment: Treatment should be guided by symptom burden, exacerbation history, and lung function, not just one parameter 2, 3

By selecting the appropriate MDI based on patient characteristics and disease severity, clinicians can optimize COPD management and improve patient outcomes.